$ACOG
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Financial Services
Sector
Financial - Conglomerates
Industry
Michael E. McFadden
CEO
5
Employees
$5.34
Current Price
$72.49M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 1 | 3 | $108,630.97 | 20,082 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 1 | 6 | $142,540.53 | 25,988 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 1 | 17 | $1,063,045.54 | 185,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 1 | 24 | $2,070,534.99 | 357,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 1 | 24 | $2,070,534.99 | 357,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
Upcoming Earnings
Scheduled earnings reports
EPS
Estimated-$0.27
ActualN/A
Revenue
Estimated$4.40M
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.27
ActualN/A
Revenue
Estimated$4.40M
ActualN/A
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: